Oppenheimer raised the firm’s price target on Gilead (GILD) to $115 from $105 and keeps an Outperform rating on the shares after partner Arcellx (ACLX) released new data from the Phase 2 iMMagine-1 trial for anito-cel in relapsed/refractory multiple myeloma. The firm thinks the treatment shows “a potentially best-in-class profile” and believes Arcellx’s treatment “looks as good as or better” than Legend’s (LEGN) J&J-partnered Carvykti, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Arcellx, Gilead announce new data from iMMagine-1 study of anitocabtagene autole
- Gilead enters ADC option and license pact with Tubulis, sees dilution
- Gilead announces PURPOSE 2 trial data published in NEJM
- Gilead price target raised to $96 from $70 at UBS
- Gilead price target raised to $100 from $90 at Mizuho